These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32425381)

  • 1. Flow Cytometry Based MRD and Its Impact on Survival Outcome in Children and Young Adults with ALL: A Prospective Study from a Tertiary Cancer Centre in Southern India.
    Panda SS; Radhakrishnan V; Ganesan P; Rajendranath R; Ganesan TS; Rajalekshmy KR; Bhola RK; Das H; Sagar TG
    Indian J Hematol Blood Transfus; 2020 Apr; 36(2):300-308. PubMed ID: 32425381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients.
    Tembhare PR; Narula G; Khanka T; Ghogale S; Chatterjee G; Patkar NV; Prasad M; Badrinath Y; Deshpande N; Gudapati P; Verma S; Sanyal M; Kunjachan F; Mangang G; Gujral S; Banavali S; Subramanian PG
    Front Oncol; 2020; 10():577. PubMed ID: 32391267
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world utility of early measurable residual disease assessments by multi-parametric flow cytometry in adult patients with B-lymphoblastic leukemia receiving Hyper-CVAD induction chemotherapy.
    Nedumannil R; Ritchie D; Bajel A; Ng AP; Harrison SJ; Westerman D
    Eur J Haematol; 2023 Feb; 110(2):168-176. PubMed ID: 36321745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
    Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
    Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia.
    Davydova Y; Galtseva I; Kapranov N; Nikiforova K; Aleshina O; Chabaeva Y; Isinova G; Kotova E; Sokolov A; Troitskaya V; Kulikov S; Parovichnikova E
    Diagnostics (Basel); 2022 Dec; 13(1):. PubMed ID: 36611312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
    Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
    J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction chemotherapy in children with acute lymphoblastic leukemia.
    Koh KN; Park M; Kim BE; Im HJ; Park CJ; Jang S; Chi HS; Seo JJ
    Korean J Pediatr; 2010 Nov; 53(11):957-64. PubMed ID: 21218018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Minimal residual disease in acute lymphoblastic leukemia: a new concept of complete remission].
    Bastida Vilá P; Palacio García C; Solsona Riera M; Ortega Aramburu JJ; Sánchez de Toledo Codina J
    An Pediatr (Barc); 2005 Nov; 63(5):390-5. PubMed ID: 16266612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of minimal residual disease on relapse in childhood acute lymphoblastic leukemia: Lessons learnt from a tertiary cancer center in India.
    Mishra V; Jain S; Anand V; Malhotra P; Tejwani N; Kapoor G
    Pediatr Hematol Oncol; 2023; 40(6):517-528. PubMed ID: 36930957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia.
    Jovanovska A; Martinova K; Kocheva S; Trajkova-Antevska Z; Coneska-Jovanova B; Panovska-Stavridis I; Stankovikj S; Trajkova S; Dimovski A
    Open Access Maced J Med Sci; 2019 Sep; 7(17):2818-2823. PubMed ID: 31844443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
    Pemmaraju N; Kantarjian H; Jorgensen JL; Jabbour E; Jain N; Thomas D; O'Brien S; Wang X; Huang X; Wang SA; Konopleva M; Konoplev S; Kadia T; Garris R; Pierce S; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2017 Mar; 92(3):279-285. PubMed ID: 28052371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
    Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow Cytometry-Based Detection of Minimal/Measurable Residual Disease Predicts Survival Outcomes in Pediatrics, Adolescents, and Young Adults With T-acute Lymphoblastic Leukemia.
    Balasubramanian P; Singh J; Ranjan A; Tanwar P; Bakhshi S; Chopra A
    Cureus; 2024 Jun; 16(6):e61705. PubMed ID: 38975365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of measurable residual disease based on multiparameter flow cytometry in childhood acute myeloid leukemia.
    Huo Y; Guan XM; Dou Y; Wen XH; Guo YX; Shen YL; An XZ; Yu J
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Nov; 23(11):1111-1118. PubMed ID: 34753542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.